Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an Effective Regimen in Relapsed Diffuse Large B-cell Lymphoma.

Barton S, Hawkes EA, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Attygalle A, Horwich A, Potter M, Ethell M, Dearden C, Gleeson M, Chau I.

Eur J Haematol. 2014 Jul 14. doi: 10.1111/ejh.12416. [Epub ahead of print]

PMID:
25039915
[PubMed - as supplied by publisher]
2.

FcγRIIa and FcγRIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease.

Sclafani F, Gonzalez de Castro D, Cunningham D, Hulkki-Wilson S, Peckitt C, Capdevila J, Glimelius B, Rosello Keranen S, Wotherspoon A, Brown G, Tait D, Begum R, Thomas J, Oates J, Chau I.

Clin Cancer Res. 2014 Jul 1. pii: clincanres.0674.2014. [Epub ahead of print]

PMID:
24987061
[PubMed - as supplied by publisher]
3.

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju121. doi: 10.1093/jnci/dju121. Print 2014 Jul.

PMID:
24957073
[PubMed - in process]
4.

Investigational therapies targeting the ErbB family in oesophagogastric cancer.

Moorcraft SY, Chau I.

Expert Opin Investig Drugs. 2014 Jun 20:1-15. [Epub ahead of print]

PMID:
24949530
[PubMed - as supplied by publisher]
5.

EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy.

Chand M, Bhangu A, Wotherspoon A, Stamp GW, Swift RI, Chau I, Tekkis PP, Brown G.

Ann Oncol. 2014 Apr;25(4):858-63. doi: 10.1093/annonc/mdu029.

PMID:
24667718
[PubMed - in process]
6.

Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein.

Eram MS, Bustos SP, Lima-Fernandes E, Siarheyeva A, Senisterra G, Hajian T, Chau I, Duan S, Wu H, Dombrovski L, Schapira M, Arrowsmith CH, Vedadi M.

J Biol Chem. 2014 Apr 25;289(17):12177-88. doi: 10.1074/jbc.M113.523183. Epub 2014 Mar 14.

PMID:
24634223
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.

Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6.

PMID:
24613126
[PubMed - indexed for MEDLINE]
8.

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1430-6. doi: 10.1016/j.ejca.2014.02.002. Epub 2014 Feb 28.

PMID:
24582914
[PubMed - indexed for MEDLINE]
9.

A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers.

Sclafani F, Smyth E, Cunningham D, Chau I, Turner A, Watkins D.

Clin Colorectal Cancer. 2014 Jun;13(2):94-9. doi: 10.1016/j.clcc.2013.11.003. Epub 2013 Nov 13.

PMID:
24332356
[PubMed - in process]
10.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators.

Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.

PMID:
24332238
[PubMed - indexed for MEDLINE]
Free Article
11.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
[PubMed - indexed for MEDLINE]
12.

Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer.

Chand M, Swift RI, Tekkis PP, Chau I, Brown G.

Br J Cancer. 2014 Jan 7;110(1):19-25. doi: 10.1038/bjc.2013.603. Epub 2013 Dec 3.

PMID:
24300971
[PubMed - indexed for MEDLINE]
13.

Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel.

Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, Seevaratnam R, Cardoso R, McLeod R, Dixon M, Yohanathan L, Lourenco LG, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn NG.

JAMA Surg. 2014 Jan;149(1):18-25. doi: 10.1001/jamasurg.2013.3959.

PMID:
24225775
[PubMed - indexed for MEDLINE]
14.

GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.

Hawkes EA, Barton S, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Horwich A, Potter M, Ethel M, Dearden C, Chau I.

Ann Hematol. 2014 May;93(5):827-34. doi: 10.1007/s00277-013-1930-y. Epub 2013 Oct 26.

PMID:
24158386
[PubMed - indexed for MEDLINE]
15.

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I.

Ann Oncol. 2013 Dec;24(12):3123-8. doi: 10.1093/annonc/mdt408. Epub 2013 Oct 20.

PMID:
24146218
[PubMed - indexed for MEDLINE]
16.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators.

Lancet. 2014 Jan 4;383(9911):31-9. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.

PMID:
24094768
[PubMed - indexed for MEDLINE]
17.

What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel.

Dixon M, Mahar A, Paszat L, McLeod R, Law C, Swallow C, Helyer L, Seeveratnam R, Cardoso R, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn N.

Surgery. 2013 Nov;154(5):1100-9. doi: 10.1016/j.surg.2013.05.021. Epub 2013 Sep 26.

PMID:
24075275
[PubMed - indexed for MEDLINE]
18.

MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?

Yu SK, Tait D, Chau I, Brown G.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):505-11. doi: 10.1016/j.ijrobp.2013.06.2052.

PMID:
24074924
[PubMed - indexed for MEDLINE]
19.

The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis.

Tam HH, Collins DJ, Brown G, Chau I, Cunningham D, Leach MO, Koh DM.

Br J Radiol. 2013 Oct;86(1030):20130281. doi: 10.1259/bjr.20130281. Epub 2013 Aug 30.

PMID:
23995873
[PubMed - indexed for MEDLINE]
20.

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H, Wadsley J, Maisey N, Chau I, Hill M, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater J, Seymour M.

Eur J Cancer. 2013 Nov;49(16):3507-16. doi: 10.1016/j.ejca.2013.06.017. Epub 2013 Aug 13.

PMID:
23953030
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk